Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein particle analysis comparing simvastatin and fenofibrate.

J M Bard1, H J Parra, G Luc

  • 1Serlia, Institut Pasteur, Lille, France.

Atherosclerosis
|December 1, 1991
PubMed
Summary

Fenofibrate and simvastatin alter lipoprotein particles differently in hypercholesterolemia. Fenofibrate increased LpAII:AI and decreased LpE:B and LpCIII:B more than simvastatin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hypercholesterolemia, from screening to treatment: Who, why and how to manage].

La Revue de medecine interne·2020
Same author

Psychological predictors of the combined adoption of physical exercise and dietary change among adults with hypercholesterolemia.

Revue d'epidemiologie et de sante publique·2018
Same author

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

[Statin treatment must be personalized].

La Revue de medecine interne·2018
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Consensus statement on the management of dyslipidaemias in adults.

Annales d'endocrinologie·2017

Area of Science:

  • Lipid metabolism
  • Pharmacology
  • Cardiovascular medicine

Background:

  • Primary hypercholesterolemia is a condition characterized by elevated cholesterol levels.
  • Lipoprotein particles play a crucial role in lipid transport and cardiovascular risk.
  • Understanding drug-induced changes in lipoprotein subclasses is essential for effective treatment.

Purpose of the Study:

  • To compare the effects of fenofibrate and simvastatin on specific lipoprotein particles in patients with primary hypercholesterolemia.
  • To analyze changes in lipoprotein composition based on apolipoprotein content.
  • To elucidate differential impacts of these lipid-lowering agents on lipoprotein structure.

Main Methods:

  • A double-blind, randomized study comparing fenofibrate (200 mg b.i.d.) and simvastatin (20 mg daily, potentially doubled).

Related Experiment Videos

  • Patients with persistent high cholesterol after placebo were randomized.
  • Lipoprotein particles (LpAI, LpAII:AI, LpE:B, LpCIII:B) were analyzed at 6 and 10 weeks.

    • Main Results:

    • Fenofibrate significantly increased apolipoprotein AI and LpAII:AI levels.
    • Simvastatin showed a more pronounced effect on apolipoprotein B.
    • Both drugs decreased LpE:B and LpCIII:B, with fenofibrate being more effective at week 6.

    Conclusions:

    • Fenofibrate and simvastatin induce distinct structural modifications in lipoprotein particles.
    • These drug-specific changes are not evident from total apolipoprotein analysis alone.
    • The observed differences likely reflect the varying mechanisms of action of fenofibrate and simvastatin.